{"paper_id":"f77702dc-9651-4ddc-9379-0444d82b8d5b","body_text":"Abstract\nPurpose\nTo compare the efficacy of the oral dienogest versus triptorelin acetate injection for treatment of premenopausal menorrhagia and pelvic pains in women with uterine adenomyosis.\nMethods\nA total of 41 patients with adenomyosis suffering from pelvic pains and menorrhagia were recruited. First group was managed with oral dienogest (2 mg/day, orally) while the second group received triptorelin acetate (3.75 mg/4 weeks, subcutaneous injection) for 16 weeks. Outpatient follow-up was undertaken after 8 weeks but mean values were calculated at baseline and after 16 weeks (end of treatment).\nResults\nA total of 41 women were allocated to treatment with dienogest (n = 22) or triptorelin acetate (n = 19); 19 (86.4 %) and 18 (94.7 %) % of the respective groups completed the trial. Significant reductions in pelvic pains after 16 weeks treatment were obtained in both groups demonstrating the equivalence of dienogest relative to triptorelin acetate. Triptorelin acetate was more effective in controlling of menorrhagia and reduction of uterine volume.\nConclusions\nDienogest may be a valuable alternative to depot triptorelin acetate for treatment of premenopausal pelvic pains in women with uterine adenomyosis.\nSimilar content being viewed by others\nReferences\nWang PH, Su WH, Sheu BC, Liu WM (2009) Adenomyosis and its variance: adenomyoma and female fertility. Taiwan J Obstet Gynecol 48:232–238\nKitawaki J (2006) Adenomyosis: the pathophysiology of an oestrogen-dependent disease. Best Pract Res Clin Obstet Gynaecol 20:493–502\nWood C (2001) Adenomyosis: difficult to diagnose, and difficult to treat. Diagn Ther Endosc 7:89–95\nKitamura Y, Allison SJ, Jha RC, Spies JB, Flick PA, Ascher SM (2006) MRI of adenomyosis: changes with uterine artery embolization. AJR Am J Roentgenol 186:855–864\nSheng J, Zhang WY, Zhang JP, Lu D (2009) The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 79:18993\nNelson JR, Corson SL (1993) Long-term management of adeno-myosis with a gonadotropin-releasing hormone agonist: a case report. Fertil Steril 59:441–443\nAhmed B, Aboubakr E, Alaa M (2012) Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand 91:489–495\nOettel M, Breitbarth H, Elger W et al (1999) The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care 4:2–13\nKöhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO (2010) A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 108(1):21–25\nDueholm M, Lundorf E, Hansen ES, Ledertoug S, Sørensen JS, Olesen F (2001) Magnetic resonance imaging and transvaginal ultrasonography for diagnosis of adenomyosis. Fertil Steril 76:588–594\nNishida M, Takano K, Arai Y, Ozone H, Ichikawa R (2010) Conservative surgical management for diffuse uterine adenomyosis. Fertil Steril 94(2):715–719\nGrimbizis GF, Mikos T, Tarlatzis B2 (2014) Uterus-sparing operative treatment for adenomyosis. Fertil Steril 101(2):472–487\nStrowitzki T, Marr J, Gerlinger C et al (2010) Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 25:633–641\nHarada M, Osuga Y, Izumi G, Takamura M, Takemura Y, Hirata T, Yoshino O, Koga K, Yano T, Taketani Y (2011) Dienogest, a new conservative strategy for extragenital endometriosis: a pilot study. Gynecol Endocrinol 27(9):717–720\nHirata Tetsuya, Izumi Gentaro, Takamura Masashi, Saito Ako, Nakazawa Akari, Harada Miyuki, Hirota Yasushi, Koga Kaori, Fujii Tomoyuki, Osuga Yutaka (2014) Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol Endocrinol 30(10):726–729\nFoster RH, Wilde MI (1998) Dienogest. Drugs 56:825–833\nHorie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N (2005) Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8productionvi a nuclear factor kappaB inactivation in endometriotic stromalcells. Fertil Steril 83:1530–1535\nYamanaka A, Kimura F, Kishi Y, Takahashi K, Suginami H, Shimizu Y, Murakami T (2014) Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells. Eur J Obstet Gynecol Reprod Biol 179:170–174\nKang JL, Wang XX, Nie ML, Huang XH (2009) Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol Obstet Invest 69:73–77\nMorelli Michele, Rocca Morena Luigia, Venturella Roberta, Mocciaro Rita, Zull Fulvio (2013) Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis: a retrospective study. Gynecol Endocrinol 29(4):305–308\nHudelist G, Oberwinkler KH, Singer CF et al (2009) Combination of transvaginal sonography and clinical examination for preoperative diagnosis of pelvic endometriosis. Hum Reprod 24:1018–1024\nFedele L, Bianchi S, Dorta M, Arcaini L, Zanotti F, Carinelli S (1992) Transvaginal ultrasonography in the diagnosis of diffuse adenomyosis. Fertil Steril 58:94–97\nKhan KN, Kitajima M, Hiraki K, Fujishita A, Nakashima M, Ishimaru T, Masuzaki H (2010) Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma. Hum Reprod 25(11):2878–2890\nGrow DR, Filer RB (1991) Treatment of adenomyosis with long-term GnRH analogues: a case report. Obstet Gynecol 78:538–539\nGraser T, Muller A, Mellinger U, Muck AO, Lippert TH, Oette LM (2000) Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest—a dose-ranging study. Maturitas 35:253–261\nIrahara M, Harada T Momoeda M, Tamaki Y (2007) Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol 6:223–228\nNagata C, Yanagida S, Okamoto A et al (2012) Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. J Obstet Gynaecol Res 38:639–644\nNapolitano M, Dolce A, Celenza G, Grandone E, Perilli MG, Siragusa S, Carta G, Orecchioni A, Marian G (2014) Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses. Ann Hematol 93:557–563\nWarner PE, Critchley HO, Lumsden MA et al (2004) Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 190:1224–1229\nParsanezhad M, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, Frank V, Schmidt E (2010) A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 93:192–198\nBazot M, Cortez A, Darai E, Rouger J, Chopier J, Antoine JM et al (2001) Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod 16:2427–2433\nConflict of interest\nNo potential conflict of interest relevant to this article was reported.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nFawzy, M., Mesbah, Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet 292, 1267–1271 (2015). https://doi.org/10.1007/s00404-015-3755-5\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-015-3755-5","source_license":"CC0","license_restricted":false}